Rating Rationale
November 09, 2022 | Mumbai
Alembic Pharmaceuticals Limited
Ratings Reaffirmed; NCD Withdrawn
 
Rating Action
Total Bank Loan Facilities RatedRs.600 Crore
Long Term RatingCRISIL AA+/Stable (Reaffirmed)
 
Rs.300 Crore Non Convertible DebenturesCRISIL AA+/Stable (Withdrawn)
Rs.200 Crore Non Convertible DebenturesCRISIL AA+/Stable (Withdrawn)
Rs.750 Crore Commercial PaperCRISIL A1+ (Reaffirmed)
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its ‘CRISIL AA+/Stable/CRISIL A1+’ ratings on the bank facilities and commercial paper programme of Alembic Pharmaceuticals Limited (Alembic Pharma). The rating on the NCDs totalling Rs 500 crore are also withdrawn as per client request, following repayment of the same, and confirmation from the trustee. The withdrawal is in line with CRISIL Ratings policy for withdrawal of ratings.

 

Consolidated revenue declined 2% on-year in fiscal 2022 due to de-growth in the US portfolio, given intense price erosion. Healthy pick-up was witnessed in domestic sales, which grew by 29% on-year in fiscal 2022. In the first quarter of fiscal 2023, revenue degrew by 5% on-year due to lower volume in the active pharmaceutical ingredients (API) segment. Revenue growth is likely to be modest in fiscal 2023; steady demand for existing products and new product launches in the international and domestic segments would support revenue growth momentum of 8-10% over the medium term.

 

Operating margin moderated to 17.3% in fiscal 2022 from 28.9% in fiscal 2021 due to sharp increase in the raw material and freight costs as well as lower realisations for few key products. The margin moderation also factors in impact of Rs 122 crore in the fourth quarter of fiscal 2022 towards the accelerated amortisation of intangible assets of Aleor Dermaceuticals Ltd (Aleor) on it becoming the wholly-owned subsidiary of the company. Margin is expected to moderate further in fiscal 2023 given the sustained elevated costs, pricing pressure in the US, and continued research and development (R&D) expenses, before improving to 18-20% over the medium term.

 

Working capital intensity remains moderately high. Gross current assets are expected at 180-200 days over the medium term (193 days as on March 31, 2022), given the focus on maintaining larger inventory to capitalise on any market opportunity and avoid any supply-side disruption. The company incurred sizeable, debt-funded capital expenditure (capex) over the past few fiscals towards specialised generics. Capex is expected at Rs 200-400 crore annually over the medium term. Financial risk profile remains healthy, with only short-term debt outstanding and healthy cash accrual, translating into comfortable debt protection metrics.

 

The ratings continue to reflect the strong position of Alembic Pharma in the domestic formulations market, growing presence in the international generics segment, and healthy financial risk profile. These strengths are partially offset by average profitability due to sizeable R&D expenditure, high share of the acute therapeutic segment in domestic formulations and exposure to intensifying pricing pressure and regulatory risks.

Analytical Approach

CRISIL Ratings has fully consolidated the business and financial risk profiles of Alembic Pharma and its three subsidiaries and seven stepdown subsidiaries, which are strategically important to, and have a significant degree of operational integration with, Alembic Pharma. CRISIL Ratings applied a moderate consolidation approach for four associate companies and two joint venture for which the share of profit and any incremental investment required are factored in.

 

Please refer Annexure - List of entities consolidated, which shows the entities considered and their analytical treatment of consolidation

Key Rating Drivers & Detailed Description

Strengths:

Strong position in the domestic formulations market

The company is among the top 25 players in the domestic formulations market. Revenue was Rs 1,926 crore in fiscal 2022 (healthy growth of 29% on-year driven by Covid-related sales on a lower base). The company has a portfolio of about 200 formulation brands, of which three are among the top 300 domestic formulations brands in India. It has a share of 1.5% in the domestic market. Growth in the branded formulations segment will be backed by increased contribution from the chronic therapeutic segment and regular product launches, leading to volume growth.

 

Diversified presence in the international market

Revenue from the international market (including bulk drugs) was 64% of the total revenue in fiscal 2022 (72% in fiscal 2021). US is a key market for the company and sales in US forms 31% of the total revenue. Apart from the US, the company has sizeable presence in Europe, Canada, and Australia. On account of greater focus on the US, Alembic Pharma has gradually stepped up its abbreviated new drug application (ANDA) filings in the last few fiscals: 23 in fiscal 2022 from eight in fiscal 2016. In fiscal 2022, US sales degrew by 23% on-year due to significant price erosion and intense competition in the Sartan portfolio. New product launches and long-term relationships with large clients would support revenue in the regulated market over the medium term. As on June 30, 2022, Alembic Pharma had filed for 237 ANDAs, of which 167 were approved.

 

Healthy financial risk profile

Financial risk profile is healthy, as reflected in adjusted networth of over Rs 5,000 crore and low gearing of 0.12 time on March 31, 2022. Interest coverage ratio was comfortable at 53.9 times in fiscal 2022. The company incurred sizeable, debt-funded capex over the past few fiscals towards specialised generics. Capex is expected at Rs 200-400 crore annually over the medium term, to be funded by cash accrual. Thus, debt protection metrics are expected to remain comfortable. Larger-than-expected capex or debt-funded acquisition remains a key rating sensitivity factor.

 

Weakness:

Profitability constrained by high R&D expenditure, price erosion in US markets

Alembic Pharma had stepped-up R&D spends, particularly in the past 4-5 fiscals, to capitalise on differentiated generics opportunities in the US. R&D expenditure remained high at 12-14% of sales in the past to build the ANDA pipeline. With sharp increase in the raw material and freight cost and severe price erosion in the US market, the operating margin moderated to 17.3% in fiscal 2022 from 28.9% in fiscal 2021. The moderation also included Rs 122 crore of impact due to amortisation of intangible assets of Aleor on becoming a wholly-owned subsidiary of the company in the fourth quarter of fiscal 2022. Besides, high share of acute therapies in the domestic market where competition is intensifying, also impacted profitability.

 

Operating margin is expected to moderate further this fiscal due to elevated costs, pricing pressures in the US market, and R&D spend, before improving to 18-20% over the medium term. The company is also expected to rationalise its R&D spend to support the operating margin going forward. However, roll out of new product launches in differentiated generics will be critical for maintaining and enhancing operating profitability.

 

Exposure to intensifying pricing pressure and regulatory risks

The company is exposed to regulatory changes in the Indian and global markets, as reflected in increasing scrutiny and inspections by authorities, including the US Food and Drug Administration (USFDA), European Medicines Agency and TGA Australia. The general injectable and ophthalmic facility in Karkhadi, Gujarat, was re-audited by the USFDA in September 2022 and the oncology injectable facility located at Panelav was audited in October 2022. Company received few observations under form 483 for both facilities. The company is in the process of addressing the observations received. In the domestic market, the regulatory impact of Drug Pricing Control Order and ban on some fixed-dose combinations adversely affected revenue and profit in the past, and will be a monitorable.

Liquidity: Strong

Liquid surplus was Rs 61 crore as on March 31, 2022, and net cash accrual expected at over Rs 550 crore in fiscal 2023, should sufficiently cover the capex requirement. The company only has short-term debt outstanding, having repaid the NCDs in the first quarter of fiscal 2023. Working capital utilisation  averaged less than 25% over the 12 months through August 2022. Comfortable debt protection metrics, enhances the company’s fund-raising ability. The company has also raised equity through qualified institutional placement in the recent past.

 

Environment, social, and governance (ESG) profile

CRISIL Ratings believes Alembic Pharma’s ESG profile supports its strong credit risk profile.

 

The pharmaceutical sector can have a significant impact on the environment owing to greenhouse gas emissions, water use and waste generation. The sector’s social impact is characterised by impact on the health and wellbeing of consumers due to its products and on employees and local community on account of its operations.

 

Key ESG highlights

  • The company has undertaken focussed efforts towards energy conservation and achieved an overall 12% reduction in the total energy consumption in fiscal 2022. It also achieved a 5% reduction in CO2 emission during the year.
  • The company has deployed water management practices and processes all liquid waste. Also, the company recharges more water into the underground water table than what it consumes. It achieved an 18% increase in the rainwater harvested in fiscal 2022.
  • It has implemented human rights policy and prevention of sexual harassment policy. Gender diversity in Alembic Pharma is marginally lower than industry peers, with women employees comprising 5-6% of the workforce over past few years.
  • Alembic Pharma has adequate governance structure, with majority of its board comprising independent directors, presence of investor grievance redressal mechanism, whistle-blower policy and extensive disclosures.

 

There is growing importance of ESG among investors and lenders. Alembic Pharma’s continued commitment to ESG principles will play a key role in enhancing stakeholder confidence and ensure ease of raising capital from markets where ESG compliance is a key factor.

Outlook: Stable

Alembic Pharma’s business risk profile is likely to benefit from its diversified segmental and geographical presence in the pharmaceutical space, even though operating profitability will remain average due to intense competition, price erosion in US markets, inflation driven costs and R&D spend. Healthy cash generation and prudent capital spending will help sustain healthy financial risk profile over the medium term.

Rating Sensitivity Factors

Upward Factors

  • Double-digit revenue growth supported by new product launches and operating profitability improving above 20-22% on a sustained basis, resulting in better-than-expected cash generation
  • Prudent capital spending and working capital management along with healthy cash generation will ensure maintenance of healthy financial risk profile and comfortable debt protection metrics
  • Gradual build-up of liquid surpluses

 

Downward Factors

  • Lower-than-expected revenue growth and operating profitability remaining below 16-18% on a sustained basis, also impacting cash generation
  • Larger-than-expected working capital requirement or capex and acquisitions, leading to moderation in debt protection metrics

About the Company

The pharmaceuticals business of Alembic Ltd (AL), comprising domestic formulations, international generics and APIs, was transferred to Alembic Pharma following the latter’s demerger from AL effective April 1, 2010. Vadodara-based Alembic Pharma manufactures a range of formulations and bulk drugs for the domestic and international markets. It has nine manufacturing facilities for formulations and APIs and three R&D facilities.

 

Alembic Pharma is listed on the Bombay Stock Exchange and the National Stock Exchange. As on September 30, 2022, the promoters and group entities held 69.61% stake, foreign portfolio investors held 5.32%, individuals held 9.12% and the balance was held by others.

 

For the quarter ended June 30, 2022, the company reported a net loss of Rs 66 crore (profit after tax [PAT] of Rs 158 crore in the corresponding period of fiscal 2022) on net sales of Rs 1,262 crore (Rs 1,326 crore). The net loss was largely owing to continued expensing of intangibles of Aleor.

Key Financial Indicators

As on/For the period ended March 31

2022

2021

Revenue

Rs crore

5,307

5,394

Adjusted PAT

Rs crore

521

1,130

Adjusted PAT margin

%

9.8

21.0

Adjusted debt/adjusted networth

Times

0.12

0.11

Interest coverage

Times

53.94

102.89

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the ‘Annexure – Details of Instrument’ in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities – including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisil.com/complexity-levels. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size (Rs crore)

Complexity level

Rating assigned with outlook

NA

Cash Credit & Working Capital Demand Loan**

NA

NA

NA

600.00

NA

CRISIL AA+/Stable

NA

Commercial paper

NA

NA

7-365 days

750.00

Simple

CRISIL A1+

**100% interchangeability between funded and non-funded.

 

Annexure - Details of Rating Withdrawn

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size (Rs.Crore)

Complexity level

INE901L08013

Non-convertible debentures

14-Dec-18

9.00

26-Nov-21

150.00

Simple

INE901L08021

Non-convertible debentures

14-Dec-18

9.00

25-Apr-22

200.00

Simple

INE901L08039

Non-convertible debentures

19-Mar-19

8.37

18-Mar-22

150.00

Simple

 

Annexure – List of entities consolidated

Names of entities consolidated

Extent of consolidation

Rationale for consolidation

Alembic Global Holding SA

100%

Subsidiary

Aleor Dermaceuticals Ltd

100%

Subsidiary

Alembic Pharmaceutical Inc

100%

Subsidiary

Alembic Pharmaceuticals Australia Pty Ltd

100%

Stepdown subsidiary

Alembic Pharmaceuticals Europe Ltd

100%

Stepdown subsidiary

Alnova Pharmaceuticals SA

100%

Stepdown subsidiary

Alembic Pharmaceuticals Canada Ltd

100%

Stepdown subsidiary

Genius LLC

100%

Stepdown subsidiary

Alembic Labs LLC

100%

Stepdown subsidiary

Okner Realty LLC

100%

Stepdown subsidiary

Alembic Mami SPA

49%

Joint Venture

SPH Sine Alembic (Shanghai) Pharmaceutical Technology Co Ltd

44%

Joint venture

Incozen Therapeutics Pvt Ltd

50%

Associate

Rhizen Pharmaceuticals AG (RPAG)

50%

Associate

Rhizen Pharmaceuticals Inc

50%

Subsidiary of RPAG

Dahlia Therapeutics SA

50%

Subsidiary of RPAG

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 600.0 CRISIL AA+/Stable   -- 22-11-21 CRISIL AA+/Stable 18-11-20 CRISIL AA+/Stable 22-07-19 CRISIL AA+/Stable CRISIL AA+/Stable
      --   --   -- 02-07-20 CRISIL AA+/Stable 11-06-19 CRISIL AA+/Stable --
Commercial Paper ST 750.0 CRISIL A1+   -- 22-11-21 CRISIL A1+ 18-11-20 CRISIL A1+ 22-07-19 CRISIL A1+ CRISIL A1+
      --   --   -- 02-07-20 CRISIL A1+ 11-06-19 CRISIL A1+ --
Non Convertible Debentures LT 500.0 Withdrawn   -- 22-11-21 CRISIL AA+/Stable 18-11-20 CRISIL AA+/Stable 22-07-19 CRISIL AA+/Stable CRISIL AA+/Stable
      --   --   -- 02-07-20 CRISIL AA+/Stable 11-06-19 CRISIL AA+/Stable --
All amounts are in Rs.Cr.
 
 
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Cash Credit & Working Capital Demand Loan** 50 Kotak Mahindra Bank Limited CRISIL AA+/Stable
Cash Credit & Working Capital Demand Loan** 50 Kotak Mahindra Bank Limited CRISIL AA+/Stable
Cash Credit & Working Capital Demand Loan** 100 Citibank N. A. CRISIL AA+/Stable
Cash Credit & Working Capital Demand Loan** 100 The Hongkong and Shanghai Banking Corporation Limited CRISIL AA+/Stable
Cash Credit & Working Capital Demand Loan** 100 Axis Bank Limited CRISIL AA+/Stable
Cash Credit & Working Capital Demand Loan** 200 HDFC Bank Limited CRISIL AA+/Stable
This Annexure has been updated on 09-Nov-2022 in line with the lender-wise facility details as on 20-Aug-2021 received from the rated entity.
**100% interchangeability between funded and non-funded
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
CRISILs Bank Loan Ratings
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt
CRISILs Criteria for Consolidation
Understanding CRISILs Ratings and Rating Scales

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Anuj Sethi
Senior Director
CRISIL Ratings Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Aditya Jhaver
Director
CRISIL Ratings Limited
B:+91 22 3342 3000
aditya.jhaver@crisil.com


Parth Shah
Manager
CRISIL Ratings Limited
B:+91 22 3342 3000
Parth.Shah@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html